FDA Determines Regulatory Review Period for ENABLEX Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ENABLEX, a human drug product, in accordance with federal regulations, following a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.